J Breast Cancer.  2007 Jun;10(2):134-140. 10.4048/jbc.2007.10.2.134.

Experience of Ovarian Function Suppression Therapy: Endocrine Response Preand Perimenopausal Korean Breast Cancer Patients in the Adjuvant Setting

• Lee JS
• Chang MA
• Ko BK
• Hong SJ
• Kim HJ
• Son BH
• Kim SB
• Ahn JH
• Kwack BS
• Ahn SH

• KMID: 1745054
• DOI: http://doi.org/10.4048/jbc.2007.10.2.134

Abstract

PURPOSE: Published Early Breast Cancer Trialists' Collaborative Group overview results have been the beneficial effects of tamoxifen and ovarian ablation for pre and perimenopausal women with node negative breast cancer. Chemotherapy and Luteinizing Hormone Releasing Hormone (LHRH) agonists (medical ovarian ablation) have been shown to be effective adjuvant therapies for early stage breast cancer in several clinical trials however, the efficacy and tolerance of LHRH agonists in Korean breast cancer patients has not been evaluated.
METHODS
Three thousand one hundred fifty breast cancer patients were treated at Asan Medical Center between January 2003 and December 2005. We selected 185 patients with node negative early breast cancer who were endocrine responsive (more than intermediate intensity), with a tumor size more than 1 cm, and who were reluctant to undergo chemotherapy due to the side effects. They received LHRH agonists (Zoladex(R) 3.6 mg) every 28 days with tamoxifen for two years. We prospectively evaluated mammography, chest PA, and physical examination every six months and evaluated the side effects and quality of life.
RESULTS
The mean age was 43.5 yr, and the mean tumor size was 1.62 cm. One hundred sixty-two patients had Stage I, and 23 Stage II disease. The incidence of severe menopausal symptoms was 24.1%, but these symptoms were reported to be "tolerable" during the two year follow-up. Quality of life and physical activity were essentially unchanged. The median follow-up duration was 18 months, and there was no local recurrence or distant metastases during the study.
CONCLUSION
Adjuvant therapy with LHRH agonists is safe and tolerable, and may be an alternative to chemotherapy for pre-and perimenopausal women with hormone responsive early breast cancer who are reluctant to undergo chemotherpy.

Keyword

Ovarian function suppression; Luteinizing Hormone Releasing Hormone analogue; Breast cancer; Side effect

MeSH Terms

Breast Neoplasms*
Breast*
Chungcheongnam-do
Drug Therapy
Female
Follow-Up Studies
Gonadotropin-Releasing Hormone
Humans
Incidence
Mammography
Motor Activity
Neoplasm Metastasis
Physical Examination
Prospective Studies
Quality of Life
Recurrence
Tamoxifen
Thorax
Gonadotropin-Releasing Hormone
Tamoxifen

Figure

• 

  Fig 1 The change of serum mean Estradiol (E2) after Goserelin injection.

Reference

1. Son BH, Kwack BS, Kim JK, Kim HJ, Hong SJ, Lee JS, et al. Changing patterns in the clinical charateristics of Korean Patients with breast cancer during the last 15 years. Arch Surg. 2006. 141:155–160.

2. Korean Breast. Nationwide Korean Breast Cancer Data of 2002. J Korean Breast Cancer Soc. 2004. 7:72–83.

3. Ahn SH. Korean Breast Cancer Society. Clinical Charateristics of breast cancer patient in Korea in 2000. Arch Surg. 2004. 139:27–30.

4. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting Highlights: International Expert Consensus on the primary therapy of early breast caner. Ann Oncol. 2005. 16:1569–1583.

5. Miller AB, Hoogstraten B, Staquwt M, Winkler A. Reporting results of cancer treatment. Cancer. 1981. 47:207–214.

6. Early Breast. Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival; an overview if the randomized trials. Lancet. 2005. 365:1687–1717.

7. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998. 352:930–942.

8. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate and flurouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association. J Clin Oncol. 2002. 20:4628–4635.

9. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast caner: a randomozied trial. J Natl Cancer Inst. 2003. 95:1833–1846.

10. National Institutes of Health Consensus Developement Conference statement. Adjuvant therapy for breast caner. 2000. J Natl Cancer Inst Monogor. 2001. 93:979–989.

11. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003. 21:3357–3365.

12. Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholsen RI. The use of anjHRH agonist in advanced premenopausal breast cancer. Br J Cancer. 1986. 53:629–636.

13. Jonat W. Zoladex versus CMF adjuvant therapy in pre/perimenopausal breast cancer:tolerability and amenorrhea comparisions. Pro Am Soc Clin Oncol. 2000. 19:87.

14. Wallwiener D, Possinger K, Bonder G, Schmid P, Untch M, Kosse V, et al. Leuprorelin acetate vs. CMF in the adjuvant treatment of premenopausal women with ER/PR- positive, node-positive breast cancer: interim results of the TABLE study. Pro Am Soc Clin Oncol. 2001. 20:34a.

15. Klijin J, de Jong F. Treatment with a leuteinaising-hormone releasing hormone analogue (buserelin) in premonopausal patients with metastatic breast cancer. Lancet. 1982. 1:1213–1216.

16. Robertson JF, Blamey RW. The use of gonadotrophin-releasing hormone (GnRH) agonist in early and advanced breast cancer in pre-and perimenopausal women. Euro J Cancer. 2003. 39:861–869.

17. Robertson JF, Walker KJ, Nicholson RI, Blamey RW. Combined endorine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. Br J Surgery. 1989. 76:1262–1265.